45. 好酸球性多発血管炎性肉芽腫症 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 45 / 薬物数 : 39 - (DrugBank : 19) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 100

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
ANTI-interleukin 5 (IL-5) humanized monoclonal
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
ANTI-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Autologous peripheral blood stem cell transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Azathioprine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-003318-10-FR   France
      2016   Phase 3   EUCTR2016-000627-53-FR   France
   Hospices Civils de Lyon
      1996   Phase 4   NCT00399399   Switzerland
Benralizumab
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca
      2025   Phase 3   NCT06512883   Brazil;Canada;Mexico;Turkey;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Corticosteroid and azathioprine
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00647166   France
Cyclophosphamide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-003318-10-FR   France
      2016   Phase 3   EUCTR2016-000275-25-FR   France
   Amano Koichi
      2023   Phase 3   JPRN-jRCT2041220136   -
   Assistance Publique - Hôpitaux de Paris
      2016   Phase 3   NCT02807103   France
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Hospices Civils de Lyon
      1996   Phase 4   NCT00399399   Switzerland
   University of Parma
      2008   Phase 2   NCT00751517   Italy
Cyclophosphamide, azathioprine,prednisone,methylprednisolone
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Depemokimab
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
Fasenra
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States
GSK3511294
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
HPC cell infusion
   Mounzer Agha
      2016   Early Phase 1   NCT02728271   -
Human normal immunoglobulin
   TEIJIN PHARMA LIMITED
      2006   Phase 3   JPRN-jRCT2080220238   -
Hydroxychloroquine
   Guy's and St Thomas' NHS Foundation Trust
      2020   Phase 4   NCT04316494   United Kingdom
Imurel
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-003318-10-FR   France
Imurel 25 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000627-53-FR   France
Infliximab
   Assistance Publique - Hôpitaux de Paris
      2004   -   NCT00307593   France
L04ac06
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Laboratory experiments before and after mepolizumab treatment
   University Medical Center Groningen
      2024   -   NCT06298448   Netherlands
Mabthera
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000627-53-FR   France
MEDI-563
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Mepolizumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-003318-10-FR   France
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   Brigham and Women's Hospital
      2007   Phase 1/Phase 2   NCT00527566   United States
   Children's Hospital Medical Center, Cincinnati
      2001   Phase 1/Phase 2   NCT00266565   United States
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline
      2015   Phase 3   NCT03298061   Belgium;Canada;France;Germany;Japan;United Kingdom;United States
      2014   Phase 3   NCT02020889   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research Ltd
      2015   Phase 3   EUCTR2014-003162-25-GB   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-DE   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-BE   Belgium;Canada;Germany;Japan;United Kingdom;United States
   Taniguchi Masami
      2024   Phase 4   JPRN-jRCTs031230675   -
   University Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
      2008   Phase 2   EUCTR2006-001791-20-DE   Germany
   University of Schleswig-Holstein
      2008   Phase 2   NCT00716651   Germany
Mesna
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000275-25-FR   France
Methotrexate
   University of Parma
      2008   Phase 2   NCT00751517   Italy
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States
Mycophenolate mofetil,methotrexate
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France
Naltrexone hydrochloride
   University of Pennsylvania
      2019   Phase 2   NCT03482479   Canada;United States
NS-229
   NS Pharma, Inc.
      2023   Phase 2   NCT06046222   Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
Nucala
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline
      2018   -   NCT03557060   Japan
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
Nucala 100 MG powder FOR solution FOR injection
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Plaquenil - hydroxychloroquine 200MG film coated tablets
   Guy's and St. Thomas' NHS Foundation Trust
      2020   Phase 4   EUCTR2018-001268-40-GB   United Kingdom
Prednisolone
   GlaxoSmithKline
      2015   Phase 3   NCT03298061   Belgium;Canada;France;Germany;Japan;United Kingdom;United States
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006055   United States
   Fernando Fervenza
      2007   Phase 2   NCT00424749   United States
Prednisone, methylprednisolone,cyclophosphamides
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France
Rituximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000627-53-FR   France
      2016   Phase 3   EUCTR2016-000275-25-FR   France
   Amano Koichi
      2023   Phase 3   JPRN-jRCT2041220136   -
   Assistance Publique - Hôpitaux de Paris
      2016   Phase 3   NCT02807103   France
      2004   -   NCT00307593   France
   Fernando Fervenza
      2007   Phase 2   NCT00424749   United States
SB-240563
   GlaxoSmithKline Research Ltd
      2015   Phase 3   EUCTR2014-003162-25-GB   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-DE   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-BE   Belgium;Canada;Germany;Japan;United Kingdom;United States
   University Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
      2008   Phase 2   EUCTR2006-001791-20-DE   Germany
Tezepelumab
   Imperial College London
      2024   Phase 2   NCT06230354   United Kingdom